br different conditions to study the value of whole
different conditions to study the value of whole-body MRI in its two most validated indications. These findings should not be extrapolated to other cancers involving the skeleton [52,53]. A third limitation is the inclusion of patients at relatively early stages of skeletal dissemination so that our results might not be applied to patients with more advanced disease . Finally, we did not obtain histolog-ical confirmation and positive findings were considered as bone metastases or MM foci at MRI .
In conclusion, our results suggest a cranio-caudal increase in the prevalence of bone metastases in PCa, whereas the distribution of lesions in MM is more homo-geneous, with no gradient. The assessment of the axial skeleton using MRI (thoraco-lumbar spine and pelvis) is suf-ficient to detect bone metastases in PCa, whereas coverage of the entire Fulvestrant with whole-body MRI seems nec-essary to detect MM involvement.
Disclosure of interest
The authors declare that they have no competing interest.
 Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017;71:630—42.
 Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 2006;42:1539—43.  Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2014;25:124—37.  Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaef-fer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 2017;14:15—25.
 deSouza NM, Liu Y, Chiti A, Oprea-Lager D, Gebhart G, Van Beers BE, et al. Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer 2018;91:153—63.
Whole-body MRI of bones lesions 301
 Garnon J, Koch G, Caudrelier J, Tsoumakidou G, Cazzato RL, Gangi A. Expanding the borders: image-guided procedures for the treatment of musculoskeletal tumors. Diagn Interv Imaging 2017;98:635—44.
 Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and sur-vival. Cancer 1975;36:842—54.
 Lauenstein TC, Goehde SC, Herborn CU, Goyen M, Oberhoff C, Debatin JF, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology 2004;233:139—48.  Messiou C, Kaiser M. Whole body diffusion weighted MRI–a new view of myeloma. Br J Haematol 2015;171:29—37.  Gutzeit A, Doert A, Froehlich JM, Eckhardt BP, Meili A, Scherr P, et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 2010;39:333—43.
 Lecouvet FE. Whole-body MR imaging: musculoskeletal appli-cations. Radiology 2016;279:345—65.  Padhani AR, Koh DM, Collins DJ. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 2011;261:700—18.  Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F, et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scan-ning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 2012;62:68—75.